Tech Company Financing Transactions

AnaCardio Funding Round

AnaCardio closed a $70.5 million Series B venture capital round on 9/30/2026. Investors included Novo Holdings, The Ljungstrom Family Office and Flerie Invest.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

A Working Lab Innomedicum, Nanna Svartz väg 4
Solna, 171 65
Sweden

Phone

Undisclosed

Website

www.anacardio.com

Email Address

[email protected]

Overview

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Lars Lund

        

Chief Executive Officer

Patrik Strömberg

        

Browse more venture capital transactions:

Prev: 9/30/2026: Blackswan Space venture capital transaction
Next: 9/30/2026: Miter venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary